Ardelyx Stock Price, News & Analysis

Ardelyx, Inc. (Nasdaq: ARDX) announced the presentation of post-hoc analyses from its Phase 3 T3MPO trials at the ACG 2022 Annual Scientific Meeting in Charlotte, NC, from October 21-26, 2022. The studies highlight the benefits of IBSRELA (tenapanor) in treating Irritable Bowel Syndrome with Constipation (IBS-C), including improved abdominal symptom scores and spontaneous bowel movement responses. Two posters will be presented on October 24 and 25, 2022, while a Product Theater session will discuss IBSRELA's safety and efficacy on October 24, 2022.

Ardelyx, Inc. (Nasdaq: ARDX) announced three poster presentations for its investigational phosphate absorption inhibitor, XPHOZAH (tenapanor), at the American Society of Nephrology Kidney Week 2022 from November 3-6 in Orlando, Florida. These posters will detail results from three Phase 3 trials involving adult patients with chronic kidney disease on dialysis. Collaborator Kyowa Kirin will also present findings from two Phase 3 trials in Japan. Tenapanor aims to manage hyperphosphatemia, affecting over 745,000 dialysis patients globally.

Ardelyx, Inc. (Nasdaq: ARDX) announced on Sept. 26, 2022, that its compensation committee granted options for 56,250 shares and 26,000 Restricted Stock Units (RSUs) to four new non-executive employees. Each stock option has an exercise price of $1.13 per share, equal to the trading price on the date of grant. The options and RSUs serve as inducements for employment, with vesting schedules over four years. Ardelyx's work includes innovative treatments for unmet medical needs such as IBSRELA and candidates like XPHOZAH for CKD patients.

Ardelyx, Inc. (Nasdaq: ARDX) announced its upcoming participation in several significant investor conferences. These include Citi's 17th Annual BioPharma Conference on September 8, 2022, in Boston, MA, and the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, in New York City/Virtual, where a presentation will be available on-demand. Additionally, the Ladenburg Thalmann 2022 Healthcare Conference will take place on September 29, 2022, in New York City. Ardelyx aims to develop innovative treatments for unmet medical needs, including products like IBSRELA® and XPHOZAH®.

Ardelyx reported its Q2 2022 results, highlighting a successful launch of IBSRELA for IBS-C, with net product sales of $1.6 million. The company enjoys strong market visibility, with 41% of surveyed GIs already using IBSRELA. R&D expenses significantly decreased by 62.6% to $9.7 million, while SG&A expenses fell by 6.3% to $18.9 million. The net loss improved to $26.9 million or $0.19 per share, compared to $45.2 million or $0.45 per share in Q2 2021. Additionally, a $20 million financing agreement was secured with HealthCare Royalty Partners.

Ardelyx, Inc. (Nasdaq: ARDX) announced that CEO Mike Raab will participate in a virtual fireside chat at the 2022 Wedbush PacGrow Healthcare Conference. The chat is scheduled for August 9, 2022, at 4:40 p.m. ET. Interested parties can access the live webcast through the Investor section of the Ardelyx website, with a replay available for 30 days post-conference. Ardelyx focuses on developing innovative medicines to address significant medical needs, including their approved product IBSRELA and products in development for conditions like CKD and hyperkalemia.

Ardelyx, Inc. (Nasdaq: ARDX) will hold a conference call on August 4, 2022, at 4:30 p.m. Eastern Time to discuss its second quarter 2022 financial results and provide a business overview. The call will be accessible via telephone registration through an online form, and a live audio webcast will also be available on Ardelyx's website. Ardelyx focuses on developing innovative medicines, including its approved product IBSRELA® and the pipeline candidates XPHOZAH® and RDX013, targeting significant medical needs.

On June 28, 2022, Ardelyx, Inc. (Nasdaq: ARDX) announced the granting of stock options and Restricted Stock Units (RSUs) to six new non-executive employees as employment inducements. The options total 332,483 shares, priced at $0.57, the closing stock price on the grant date, while RSUs amount to 83,375 shares. Both stock options and RSUs vest over four years. Ardelyx focuses on developing innovative medicines, including IBSRELA® and XPHOZAH®, with partnerships in Japan, China, and Canada.

Ardelyx, Inc. announced it may receive up to $20 million from HealthCare Royalty Partners for future royalties from its collaboration with Kyowa Kirin on tenapanor for hyperphosphatemia. This financing validates the potential of tenapanor in Japan. Ardelyx will get $10 million upfront, $5 million post-regulatory approval, and another $5 million upon meeting sales targets. Overall, Ardelyx could gain $85 million in non-dilutive capital from Kyowa Kirin's development progress, despite reduced royalty rates from high teens to mid-single digits during the agreement period.